3 Japanese AI Healthcare Stocks With Earnings Growth Over 11% To Watch

Warren Buffett’s warning about an expensive US stock market filled with AI hype is hard to ignore. It pushes many investors to look for more grounded stories, including in Japanese healthcare where artificial intelligence is quietly reshaping how doctors diagnose, treat, and manage patients. This article walks through three screened AI healthcare stocks in Japan, explaining how this niche may be relevant for investors to consider.

The three Japanese AI healthcare stocks in this article are a starting sample, and the full screen surfaced 6 more companies with equally compelling narratives that are not covered here. If you want to identify potential high-conviction ideas, head straight to the Transformative Artificial intelligence (AI) Healthcare Stocks screener.

Chugai Pharmaceutical (TSE:4519)

Chugai Pharmaceutical is a large Japan based drug developer that earns about ¥1.3t in annual pharmaceuticals revenue and applies AI tools to speed up early stage research decisions across that portfolio, supported by a market value of roughly ¥11.0t.

Chugai Pharmaceutical gives this screener real depth because it combines a substantial biologics portfolio with a concrete push to weave AI into how new medicines are discovered.

"Phylo and Chugai Pharmaceutical entered a collaboration to use Phylo's Biomni Lab AI platform across Chugai's drug discovery workflows, covering areas such as single cell analysis, human genetics, disease biology, and target evaluation."

What happens to Chugai Pharmaceutical’s earnings profile if one quiet shift in how early projects are selected meaningfully changes long run R&D efficiency?

If that shift in R&D efficiency is what you care about, read the full narrative for Chugai Pharmaceutical to see how AI could reshape Chugai Pharmaceutical’s long term earnings mix.

Wellness Communications (TSE:366A)

Wellness Communications runs Growbase, a cloud health management platform that uses AI to centralize medical data, support diagnostics, and personalize interventions, while its SUZAKU system applies AI to talent analytics. Most revenue comes from Health Check Solutions at about ¥13.0b, with ¥1.5b from Health Management Cloud, and the group is valued around ¥14.2b.

Wellness Communications links AI directly to real world health decisions through Growbase. Its earnings are reported to be up 5.9% in the past year and forecast growth is cited at about 25.85%, supported by a P/E of 17.4x and 14.1% ROE. The company operates in a context where changes in how payors and employers value AI driven health outcomes could influence its business environment.

Those shifts in how Wellness Communications gets paid for outcomes are exactly what the analysis report for Wellness Communications unpacks, so you can judge how durable this growth story really is.

eWeLLLtd (TSE:5038)

eWeLLLtd runs iBow, a cloud-based electronic medical record platform for home-based nursing in Japan that includes an AI home nursing report alongside billing, attendance and e-learning tools. The business carries a market value of about ¥32.1b.

For this screener, the appeal is clear. By channelling AI into home-care documentation and workflow automation, eWeLLLtd is priced at 26.5x P/E with forecast earnings growth of 20.74% and ROE projected near 32.9%. This places significant emphasis on how any change in home-care AI adoption affects the business.

That kind of expectation pressure makes it worth reading the analyst forecasts for eWeLLLtd to see how much earnings momentum needs to hold before sentiment starts to shift.

Seeking Fresh Alternatives Before They Fly

Fresh opportunities are already building breakout momentum while they stay under the radar for now. Screens age quickly. Before the best entries get caught and start dropping, act now.

• Target resilient compounding by scanning a curated 15 dividend fortresses that focuses on steady cash flows and robust coverage while yields remain attractive.
• Track early AI momentum by reviewing hand picked 60 AI infrastructure stocks positioned around data centers, chips, and power capacity before investor attention fully crowds in.
• Pursue structural demand in metals through a focused 29 top copper producer stocks set built around production scale, project pipelines, and balance sheet strength while it still gets priced modestly.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com